Insilico Medicine Forms Longevity Board to Accelerate AI-Driven Aging Research
Insilico Medicine has announced the formation of the industry’s first Longevity Board to provide scientific and strategic guidance for AI-enabled aging research. The board’s mission is to steer discovery toward therapies that reduce age-related disease burden and move health systems from reactive care to proactive healthspan extension.
Uniting Pharma Expertise with Longevity Science
The board brings together leaders from industry and academia, with Andrew Adams, Group Vice President at Eli Lilly, named as Chairman. Adams connects large-scale pharmaceutical R&D experience with translational pathways for new modalities. The inclusion of Nobel Laureate Michael Levitt adds structural biology and computational credibility. This mix aims to accelerate clinical development and regulatory alignment for longevity-directed programs.
A Strategic Shift in Extending Healthspan
The Longevity Board reflects a pragmatic trend in the field: rather than only pursuing abstract anti-aging claims, researchers now focus on drugs that treat age-related diseases such as metabolic disorders and fibrosis, then broaden indications to address underlying aging biology. Insilico calls this pursuit of dual-purpose therapeutics: targets and molecules that treat disease while modulating core aging processes. That approach de-risks translation and creates clearer clinical and commercial pathways.
AI’s Impact on Insilico’s Longevity Vision
Insilico has invested in longevity science for more than a decade. Its platform uses generative AI and high-performance computation to map molecular and cellular aging pathways, nominate targets, and design candidate molecules. AI enables systematic integration of multi-omics, druggability prediction, and biomarkers of aging to prioritize candidates for clinical testing. The Longevity Board will guide selection of biomarkers and trial designs that can demonstrate healthspan benefits in realistic timelines.
Long term, the board aims to combine Big Pharma development know-how with AI-driven discovery to produce clinically viable, dual-purpose therapies that shift care toward preserving function and preventing age-related decline.
